O-RAN-ALLIANCE
25.2.2020 10:02:10 CET | Business Wire | Press release
The O-RAN Alliance (O-RAN) and the Telecom Infra Project (TIP) have announced today a liaison agreement that ensures alignment in the shared focus area of developing interoperable open Radio Access Network (RAN) solutions.
The O-RAN Alliance is focused on the development of open, intelligent, virtualized and interoperable RAN specifications. The Alliance has already created 31 specifications, with 37 demonstrations of the technology at past MWC events, global plugfests, and more than 1 000 000 lines of code released in partnership with the Linux Foundation. Operators have begun to announce network implementations.
O-RAN Alliance’s mission and focus complements TIP’s mission of deploying end-to-end disaggregated telecom infrastructure in varying environments. With the liaison agreement O-RAN and TIP are now reaching a new level of collaboration for open RAN. The liaison allows for sharing information, referencing specifications and conducting joint testing and integration efforts.
“This new collaboration framework between O-RAN and TIP, two major initiatives in the area of open networking, will support our mission to re-shape the RAN industry towards open and intelligent mobile network infrastructure,” said Alex Jinsung Choi, COO of the O-RAN Alliance and SVP Strategy & Technology Innovation, Deutsche Telekom. “Alignment on O-RAN interoperability efforts will help the industry to speed up the delivery of commercial open RAN solutions. The establishment of the first joint O-RAN Open Test and Integration Center (OTIC) with the TIP Community Lab in Berlin is a concrete step to facilitate this multi-community approach.”
“TIP’s OpenRAN solutions are an important element of our work to accelerate innovation across all elements of the network including Access, Transport, Core & Services. Across the TIP community, we are seeing increasing demand and have achieved meaningful progress with OpenRAN deployments around the world,” said Attilio Zani, Executive Director, Telecom Infra Project. “With this collaboration framework in place, TIP and O-RAN will work together to develop interoperable 5G RAN solutions. One of our first outputs will be the release of the OpenRAN 5GNR NR Base Station Platform requirements document with normative references to the O-RAN specifications.”
About O-RAN Alliance
O-RAN Alliance is a world-wide community of more than 160 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, O-RAN Alliance’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, O-RAN Alliance publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For a short video describing O-RAN’s progress, see www.o-ran.org/videos
For more information please visit www.o-ran.org
About Telecom Infra Project
TIP is a collaborative telecom community that is evolving the infrastructure that underpins global connectivity. TIP’s mission is to accelerate the pace of innovation in next generation telecom networks, through the design, build, test and deployment of standards-based, open and disaggregated end-to-end solutions. Over the past four years, TIP has driven substantial innovation across all elements of the network including Access, Transport, Core & Services, while spanning urban through to rural market use cases. To date, it has 13 Community Labs which test, validate and integrate solutions, embarked on field trials in Africa, Latin America, Middle East and Europe. The recently launched TIP Exchange hosts 45 products from 28 member companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom